The Illusion of Safety: How Research Misled Us on Tylenol in Pregnancy

For decades, Tylenol (also called acetaminophen or paracetamol) has been considered one of the safest pain relievers for pregnant women. Doctors often recommend it as the first choice for headaches, fever, or discomfort. Unlike ibuprofen or aspirin, which are discouraged in pregnancy, Tylenol was seen as the “safe” option.

But growing research is telling a different story. A number of studies now suggest that acetaminophen may increase the risk of developmental conditions like autism and ADHD when used during pregnancy. In 2024, a massive Swedish study made headlines by declaring that those concerns were overblown. According to its authors, once certain statistical adjustments were made, there was “no association” between Tylenol use and children’s brain health.

That conclusion was splashed across media outlets and reassured millions of expectant parents. Yet experts warn the Swedish study may have given a false sense of security. When we dig deeper into how the research was done, it becomes clear that the “no risk” finding was more illusion than fact.

The Swedish Study: Big Numbers, Small Comfort

The Swedish study, published in JAMA in 2024, followed 2.48 million children born between 1995 and 2019. About 7.5% of their mothers were recorded as using acetaminophen during pregnancy. When the researchers compared exposed and unexposed children in standard analyses, they saw small increases in autism and ADHD. But when they used a special method called sibling comparison—comparing siblings within the same family, one exposed and one not—the differences disappeared.

The headline was simple: “Tylenol use in pregnancy not linked to autism or ADHD.” But the truth is more complicated.

Why the Results Are Misleading

Undercounting Use

Only 7.5% of Swedish mothers in the study were classified as acetaminophen users. That’s shockingly low. Surveys from Europe and North America consistently show that 40–65% of pregnant women use Tylenol at some point. That means five out of six real users were incorrectly lumped into the “non-user” group. When so many exposed mothers are mislabeled, the numbers collapse toward showing no difference—even if a real risk exists.

The Problem with Sibling Comparisons

Sibling comparison is meant to filter out family factors like genetics or environment. But here, it may have erased the very differences that matter. Some families carry vulnerabilities, like weaker detox systems for handling oxidative stress. These families may be especially sensitive to acetaminophen’s effects. Comparing siblings within such families can cancel out those contrasts, creating a misleading picture of safety.

Adjusting Away the Mechanism

The researchers also adjusted their analysis for over 20 factors, including infections, inflammation, and oxidative stress. But these aren’t just random confounders—they’re conditions that can make acetaminophen more toxic. By adjusting them away, the study effectively removed the biological mechanism by which harm could occur.

Missing Timing and Dose

The study only had prescription records, but most Tylenol use in pregnancy is over-the-counter. It also treated exposure as a simple “yes” or “no,” ignoring whether a mother used a single dose or took it daily for weeks. Sensitive windows, like the second trimester, were not well examined. If the risk depends on timing or dose, this study wasn’t equipped to catch it.

A Closer Look: Parker’s Rebuttal

Shortly after the Swedish study, scientist William Parker and colleagues published a detailed rebuttal. Using computer modeling, they showed how the Swedish design could produce a false “no risk” result even if acetaminophen doubled the risk of autism.

Here’s how:

• When 60% of women actually use acetaminophen but only 7.5% are counted, the signal collapses.
• When you wrongly treat inflammation and oxidative stress as confounders instead of risk enhancers, the signal disappears.
• When you compare siblings in families already vulnerable, the signal is erased.

Parker’s team concluded that the Swedish “no association” was a statistical illusion, not evidence of safety. They also gathered over 22 different lines of scientific evidence—from lab studies to biomarker data—all pointing to acetaminophen as a real hazard for developing brains.

What Other Research Shows

The Swedish study may have grabbed headlines, but it doesn’t stand alone. A wide body of research paints a much more concerning picture.

Biomarkers Tell the Tale

A 2020 study measured acetaminophen breakdown products in umbilical cord blood from nearly 1,000 newborns. The results showed a clear dose-response: the higher the acetaminophen levels, the higher the child’s risk of autism and ADHD. This kind of direct biological measurement avoids the guesswork of prescription records and provides some of the strongest evidence to date.

Consistent Meta-Analyses

When researchers pool data from many studies, the signal becomes clearer. Meta-analyses consistently find that children exposed to acetaminophen in the womb face about a 20–30% higher risk of autism or ADHD. That may sound modest, but given how many millions of children are exposed, even a 20% increase is huge in public health terms.

Animal Experiments

In animal models, perinatal acetaminophen exposure alters brain development, behavior, and learning ability—especially in conditions of oxidative stress. These experiments reinforce the idea that acetaminophen is not harmless to developing nervous systems.

Mechanisms of Harm

The biology also makes sense. Acetaminophen depletes glutathione, the body’s key antioxidant. In adults, overdose leads to liver failure through this mechanism. In fetuses and newborns, whose detox systems are immature, even ordinary doses may trigger oxidative stress, disrupt hormones, and impair brain development. If inflammation or infection is already present, the toxic impact can be magnified.

The Red Flags We Ignored

Back in 2008, researcher Stephen Schultz published a survey showing a startling 20-fold increase in regressive autism after acetaminophen use in toddlers following vaccination. Instead of being urgently replicated, this finding was brushed aside. Parents’ observations that Tylenol seemed to worsen or trigger regressions in some children were dismissed as anecdotal. In hindsight, this was a warning we should have investigated, not ignored.

A 2025 Preprint: Calling Out the Mistakes

In August 2025, a new paper made waves with its blunt title: “Evidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade.” The authors found that:

• Two-thirds of studies mistakenly adjusted away the very factors that drive toxicity.
• Three-quarters looked only at pregnancy use, ignoring postnatal exposure.
• High-risk signals, like the 2008 Schultz survey, were dismissed instead of studied further.

The message was clear: the way research has been conducted has systematically hidden risk.

Putting It All Together

Step back from the debate and the convergence is hard to deny:

• Epidemiology: Population studies show a 20–30% higher risk of autism and ADHD in exposed children.
• Biomarkers: Cord-blood levels of acetaminophen metabolites show a dose-response effect.
• Mechanisms: Oxidative stress, glutathione depletion, and endocrine disruption provide a clear path of harm.
• History: Early high-risk signals were ignored, delaying action.

The Swedish “no association” study, far from being reassuring, is a distraction from this growing body of evidence.

What Parents Need to Know

So what does this mean if you’re pregnant or planning to be? The takeaway is not panic, but caution. Tylenol is not risk-free. The safest approach is:

• Limit use whenever possible. Only take acetaminophen when truly necessary, at the lowest effective dose, and for the shortest time.
• Talk to your doctor. Never stop or start medication without medical guidance, but be aware that many providers are still catching up to the latest evidence.
• Be wary of routine use. Taking Tylenol daily for headaches, sleep, or minor aches may not be worth the potential risk.

The Bigger Question

The real question now isn’t whether acetaminophen carries risk—the weight of evidence says it does. The question is how many cases of autism, ADHD, and other developmental problems might have been prevented if early warnings had been taken seriously. For decades, pregnant women were told Tylenol was the “safe” option. If that advice was wrong, the cost has been measured in children’s futures.

REFERENCES:

1. Ahlqvist, V. H., et al. (2024). “Acetaminophen Use During Pregnancy and Risk of Autism, ADHD, or Intellectual Disability.” JAMA, 331(15): 1257–1268.
2. Parker, W., et al. (2022). “Acetaminophen Use During Pregnancy: Reconsidering Its Safety.” Life, 12(9): 1332.
3. Parker, W., et al. (2025). Evidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade. Preprint.
4. Schultz, S. T., et al. (2008). “Acetaminophen Use, Measles Vaccination, and Autistic Disorder: The Results of a Parent Survey.” Autism, 12(3): 293–307.
5. Ji, Y., et al. (2020). “Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood.” JAMA Psychiatry, 77(2): 180–189.
6. Prada, J., et al. (2025). “Evaluation of the Evidence on Acetaminophen Use and Neurodevelopmental Disorders.” Environmental Health, 24: 67.
7. Mount Sinai School of Medicine. (2025). “Prenatal Acetaminophen Use and Neurodevelopmental Risk: Evidence from High-Quality Studies.” Mount Sinai News Release.
   
8. Viberg, H., et al. (2013). “Paracetamol (Acetaminophen) Administration During Neonatal Brain Development Affects Cognitive Function and Alters Its Analgesic and Anxiolytic Response in Adult Male Mice.” Toxicological Sciences, 138(1): 139–147.